Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Astermark

Showing results (21-30 of 92) with videos related to

Pageof 10
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 10, 2022
Clinical outcome and adherence rate in Scandinavian patients with intermediate-intensity prophylaxis before and after the switch of standard half-life FVIII products to BAY 81-8973Alexandros Arvanitakis, Pål Andre Holme, Erik Berntorp, et al.
Thrombosis Research|April 27, 2005
Protein C levels can be forecasted by global haemostatic tests in critically ill patients and predict long-term survivalGunnar Nilsson, Jan Astermark, Stefan Lethagen, et al.
Therapeutic Advances in Hematology|January 30, 2026
Nine areas with outstanding challenges for hemophilia B researchJan Astermark, Cédric Hermans, Peter J Lenting, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 16, 2022
Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins: Real-world experience in the Nordic countriesAnna-Elina Lehtinen, Fariba Baghaei, Jan Astermark, et al.
European Journal of Haematology. Supplementum|June 25, 2014
Immunosuppressive agents in the treatment of inhibitors in congenital haemophilia A and B--a systematic literature reviewBritta Antonia Petra Laros-van Gorkom, Céline Falaise, Jan Astermark
Research and Practice in Thrombosis and Haemostasis|December 1, 2025
Haemophilia B: an illustrative review of current challenges and opportunitiesCedric Hermans, Jan Astermark, Sonata Šaulytė Trakymienė, et al.
Journal of Thrombosis and Haemostasis : JTH|February 8, 2020
Detection of F8 int22h inversions using digital droplet PCR and mile-post assaysEric Manderstedt, Christina Lind-Halldén, Rolf Ljung, et al.
Blood|December 29, 2005
Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia AJan Astermark, Johannes Oldenburg, Anna Pavlova, et al.
Haematologica|July 6, 2005
The Malmö International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia AJan Astermark, Johannes Oldenburg, Miguel Escobar, et al.
Journal of Thrombosis and Haemostasis : JTH|December 21, 2020
Droplet digital PCR and mile-post analysis for the detection of F8 int1h inversionsEric Manderstedt, Christina Lind-Halldén, Rolf Ljung, et al.
Pageof 10

Showing results (21-30 of 92) with videos related to

Sort By:
Pageof 10
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 10, 2022
Clinical outcome and adherence rate in Scandinavian patients with intermediate-intensity prophylaxis before and after the switch of standard half-life FVIII products to BAY 81-8973Alexandros Arvanitakis, Pål Andre Holme, Erik Berntorp, et al.
Thrombosis Research|April 27, 2005
Protein C levels can be forecasted by global haemostatic tests in critically ill patients and predict long-term survivalGunnar Nilsson, Jan Astermark, Stefan Lethagen, et al.
Therapeutic Advances in Hematology|January 30, 2026
Nine areas with outstanding challenges for hemophilia B researchJan Astermark, Cédric Hermans, Peter J Lenting, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 16, 2022
Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins: Real-world experience in the Nordic countriesAnna-Elina Lehtinen, Fariba Baghaei, Jan Astermark, et al.
European Journal of Haematology. Supplementum|June 25, 2014
Immunosuppressive agents in the treatment of inhibitors in congenital haemophilia A and B--a systematic literature reviewBritta Antonia Petra Laros-van Gorkom, Céline Falaise, Jan Astermark
Research and Practice in Thrombosis and Haemostasis|December 1, 2025
Haemophilia B: an illustrative review of current challenges and opportunitiesCedric Hermans, Jan Astermark, Sonata Šaulytė Trakymienė, et al.
Journal of Thrombosis and Haemostasis : JTH|February 8, 2020
Detection of F8 int22h inversions using digital droplet PCR and mile-post assaysEric Manderstedt, Christina Lind-Halldén, Rolf Ljung, et al.
Blood|December 29, 2005
Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia AJan Astermark, Johannes Oldenburg, Anna Pavlova, et al.
Haematologica|July 6, 2005
The Malmö International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia AJan Astermark, Johannes Oldenburg, Miguel Escobar, et al.
Journal of Thrombosis and Haemostasis : JTH|December 21, 2020
Droplet digital PCR and mile-post analysis for the detection of F8 int1h inversionsEric Manderstedt, Christina Lind-Halldén, Rolf Ljung, et al.
Pageof 10